A Phase 3, Multicenter, 20-Week, Double-Blind and 32-Week Open-Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Lumbar Spine
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2018
At a glance
- Drugs Ibuprofen (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Techfields Pharma
- 10 Sep 2018 Planned initiation date changed from 10 Aug 2018 to 30 Dec 2018.
- 01 May 2018 Planned End Date changed from 30 Aug 2019 to 30 Mar 2020.
- 01 May 2018 Planned primary completion date changed from 10 Jan 2019 to 10 Dec 2019.